VALIDATED STABILITY INDICATING RP-HPLC METHOD FOR THE SIMULTANEOUS ESTIMATION OF RILPIVIRINE AND DOLUTEGRAVIR IN BULK FORM

被引:2
作者
Reddy, K. Srinivas [1 ]
Shirisha, S. Sai [2 ]
Kumar, K. Praveen [2 ]
机构
[1] Vaagdevi Coll Pharm, Pharmacognosy & Phytochem, Warangal 506001, Telangana, India
[2] Vaagdevi Coll Pharm, Dept Pharmaceut Anal, Warangal 506001, Telangana, India
来源
INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH | 2020年 / 11卷 / 10期
关键词
Rilpivirine; Dolutegravir; RP-HPLC; Simultaneous Estimation; Stability studies; ICH Guidelines;
D O I
10.13040/IJPSR.0975-8232.11(10).4991-97
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
New simple, sensitive, and validated stability-indicating RP-HPLC method has been developed for the simultaneous estimation of Rilpivirine and Dolutegravir in its bulk form. Chromatographic separation was achieved on a Hypersil ODS (250mm x 4.6mm i.d., 5 mu m) maintained at ambient temperature by a mobile phase consisted of methanol and water (80:20v/v) and a flow rate of 1.0mL/min with a load of 20 mu L. The detection wavelength was set at 282nm. The retention time for the drugs was found to be Rilpivirine (5.14min), Dolutegravir (6.72min). The eluted compounds were detected using a UV detector. The drugs were subjected to stress degradation as per ICH Q1A. There was the interference of degradant at RT of Rilpivirine and Dolutegravir. The developed method was successfully validated according to ICH guidelines. The calibration curve was found to be linear over a range of 10-100 mu g/mL. The accuracy of the method is indicated by a good recovery in the range of Rilpivirine 99-102% and of Dolutegravir 99-102%. The limit of detection and limit of quantification of Rilpivirine was found to be LOD-0.844 mu g/ mL and LOQ-2.557 mu g/mL, and for Dolutegravir was found to be LOD-0.082 mu g/mL and LOQ-0.249 mu g/mL.
引用
收藏
页码:4991 / 4997
页数:7
相关论文
共 18 条
  • [1] [Anonymous], 2012, RANG DALESPHARMACOLO
  • [2] [Anonymous], 2012, INT J APPL GRAPH THE
  • [3] [Anonymous], 2005, ICH GUIDELINES VALID, P1
  • [4] [Anonymous], 2004, ICH GUIDELINES STABI, P1
  • [5] Balasaheb B.G., 2015, MALAYSIAN J ANAL SCI, V19, P1156
  • [6] Damle MC, 2017, INDOAMERICAN J PHARM, V7, P8830
  • [7] Fatima SS, 2017, INDO AM J PHARM SCI, V4, P359, DOI 10.5281/zenodo.375937
  • [8] Ghosh S, 2013, RES J PHARM TECHNOLO, V6, P240
  • [9] Joseph J, 2016, EUROPEAN J BIOMEDICA, P22
  • [10] Kiran B, 2015, SCI PHARM, V84, P305